The total number of records retrieved from this search are 100. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_37	Virus nameAdenovirus	Virus strainoAd/DCN/LRP	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+6 cells	In-vivo virus concentration2.0E+10 VP (on 0, 2, and 4 days)	In-vivo toxicitySlight hepatotoxicity	In-vivo resultReduction in tumor volume to 230 cubic millimeter compared to control 300 cubic millimeter after 46 days	Mode of deliveryIntravenously	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectIL-6 production increased by 3 folds as compared to normal	Clinical trialNA	PMID26471393
IDOV_38	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+4 cells	In-vivo virus concentration2.0E+10 VP (on 0, 2, and 4 days)	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 198 cubic millimeter compared to control 300 cubic millimeter after 46 days	Mode of deliveryIntravenously	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_39	Virus nameAdenovirus	Virus strainoAd/DCN/LRP-PEG-NT	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationInsertional mutant for DCN and LRP gene with NT-conjugated polyethylene glycol	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MIA PaCa-2 cell line 5.0E+4 cells	In-vivo virus concentration2.0E+10 VP (on 0, 2, and 4 days)	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 100 cubic millimeter compared to control 300 cubic millimeter after 46 days	Mode of deliveryIntravenously	Pathway inducedInhibits Wnt/β-catenin and TGF-β1 signaling pathways	Immunogenic effectNA	Clinical trialNA	PMID26471393
IDOV_357	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu (every 3 days for at total 4 treatments)	In-vivo toxicityNA	In-vivo result41% smaller tumor size compared to the negative control virus AdLacZ	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_358	Virus nameAdenovirus	Virus strainAdhz60	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1b-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive days	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu (every 3 days for at total 4 treatments)	In-vivo toxicityNA	In-vivo result70% smaller tumor size compared to the negative control virus AdLacZ	Mode of deliveryIntratumorally	Pathway inducedJNK activation induces autophagy	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_359	Virus nameAdenovirus	Virus strainAdLacZ	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationE1/E3-deleted mutant	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with temozolomide (TMZ) intraperitoneally at 50 mg/Kg for five consecutive days	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nu/nu male mice (subcutaneously injected A549 lung cancer cells, 5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu (every 3 days for at total 4 treatments)	In-vivo toxicityNA	In-vivo result30% smaller tumor size compared to the negative control virus AdLacZ	Mode of deliveryIntratumorally	Pathway inducedJNK activation induces autophagy	Immunogenic effectNA	Clinical trialNA	PMID26561948
IDOV_401	Virus nameHerpes simplex virus	Virus strainICP10PK	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant with R1 domain poorly functional in HSV-1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismXenograft male BALB/c nu/nu mice (subcutaneously injected with 1.0E+7 A3755 cells in 100 μl)	In-vivo virus concentration100 μl; 1.0E+6 PFU on day 7	In-vivo toxicityNA	In-vivo resultOn day 29 , tumor growth ratio reached 2 as compared to 13 (tumour growth ratio - dividing each tumour volume measured over time by the initial tumour volume on day 7)	Mode of deliveryIntratumorally	Pathway inducedNA	Immunogenic effectMICA and TNF-alpha expressions are upregulated	Clinical trialNA	PMID26602205
IDOV_566	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale BALB/c nu/nu mice inoculated subcutaneously with MNNG/HOS-Luc cells (5.0E+6 cells per site)	In-vivo virus concentration5.0E+7 PFU	In-vivo toxicityNA	In-vivo resultProliferating tumor cells expressing ki67 get reduced from 550 cells to 250 cells	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_567	Virus nameAdenovirus	Virus strainOBP-301 (telomelysin)	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationViral mutant with human telomerase reverse transcriptase (hTERT) promotor for selective replication in cancer cells	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with cisplatin (CDDP, 4 mg/kg body weight ) and doxorubicin (DOX, 2 mg/kg body weight )[drugs were given intraperitoneally]	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale BALB/c nu/nu mice inoculated subcutaneously with MNNG/HOS-Luc cells (5.0E+6 cells per site)	In-vivo virus concentration5.0E+7 PFU	In-vivo toxicityNA	In-vivo resultProliferating tumor cells expressing ki67 get reduced from 550 cells to 75 cells	Mode of deliveryDirect injection	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27356624
IDOV_602	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89 (10 mg/kg/d), injected intraperitoneally	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale BALB/c-nu/nu mice inoculated subcutaneously with HCT-116, 5.0E+6 cells per mouse	In-vivo virus concentration3.0E+7 PFU/d	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 0.2 cubic centimeter compared to control 1cubic centimeter after 27 days	Mode of deliveryintravenously	Pathway inducedActivates Caspase-3	Immunogenic effectNA	Clinical trialNA	PMID27374176
IDOV_603	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale BALB/c-nu/nu mice inoculated subcutaneously with HCT-116, 5.0E+6 cells per mouse	In-vivo virus concentration3.0E+7 PFU/d	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 0.76 cubic centimeter compared to control 1cubic centimeter after 27 days	Mode of deliveryintravenously	Pathway inducedActivates Caspase-3 (very small)	Immunogenic effectNA	Clinical trialNA	PMID27374176
IDOV_604	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with H89 (10 mg/kg/d), injected intraperitoneally	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale BALB/c-nu/nu mice inoculated subcutaneously with Capan-1, 3.0E+6 cells per mouse	In-vivo virus concentration3.0E+7 PFU/d	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 0.1 cubic centimeter compared to control 1cubic centimeter after 23 days	Mode of deliveryintravenously	Pathway inducedActivates Caspase-3	Immunogenic effectNA	Clinical trialNA	PMID27374176
IDOV_605	Virus nameAlphavirus	Virus strainM1	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismFemale BALB/c-nu/nu mice inoculated subcutaneously with Capan-1, 3.0E+6 cells per mouse	In-vivo virus concentration3.0E+7 PFU/d	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 0.2 cubic centimeter compared to control 1cubic centimeter after 23 days	Mode of deliveryintravenously	Pathway inducedActivates Caspase-3 (very small)	Immunogenic effectNA	Clinical trialNA	PMID27374176
IDOV_749	Virus nameAdenovirus	Virus strainAdAFPp-E1A	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral mutant with E1A gene driven by AFP promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 orthotopic liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor weight to 0.2 g compared to control 0.75 g after 18 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_750	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 orthotopic liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor weight to 0.2 g compared to control 0.75 g after 18 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_751	Virus nameAdenovirus	Virus strainAdTrack	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 orthotopic liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor weight to 0.85 g compared to control 0.75 g after 18 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_752	Virus nameAdenovirus	Virus strainAdAFPp-E1A-122	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationThe viral insertion mutant with miR-122 target sequence into AdAFPp-E1A for negatively regulating E1A gene expression	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismHepG2 subcutaneous liver xenograft tumor in Balb/c athymic nude	In-vivo virus concentrationNA	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 0.8 cubic centimeter compared to control 2.4 cubic centimeter after 15 days	Mode of deliveryintravenously	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID27450327
IDOV_829	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneNo	Virus in combination with drug/radiationViral strain in combination with DNR 300 μg/kg	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismXenograft BALB/c nu/nu female mice subcutaneously injected with 1.0E+7 × 10⁷ K562 cells in a total volume of 100 μl	In-vivo virus concentration1.0E+9 pfu/ml	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 20 cubic millimeter compared to control 880 cubic millimeter after 30 days	Mode of deliveryIntratumoral	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_830	Virus nameAdenovirus	Virus strainSG611-VSTM1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationA VSTM1 gene expression cassette containing VSTM1 cDNA, cytomegalovirus promoter and SV40 polyA was inserted into the genome of SG611 to generate SG611-VSTM1	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismXenograft BALB/c nu/nu female mice subcutaneously injected with 1.0E+7 × 10⁷ K562 cells in a total volume of 100 μl	In-vivo virus concentration1.0E+9 pfu/ml	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 80 cubic millimeter compared to control 880 cubic millimeter after 30 days	Mode of deliveryIntratumoral	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_831	Virus nameAdenovirus	Virus strainSG611	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismXenograft BALB/c nu/nu female mice subcutaneously injected with 1.0E+7 × 10⁷ K562 cells in a total volume of 100 μl	In-vivo virus concentration1.0E+9 pfu/ml	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 120 cubic millimeter compared to control 880 cubic millimeter after 30 days	Mode of deliveryIntratumoral	Pathway inducedEnhanced apoptosis activation is observed	Immunogenic effectNA	Clinical trialNA	PMID27472927
IDOV_884	Virus nameHerpes simplex virus	Virus strainJS1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationJS1 strain mutant in ICP34.5 and ICP47	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for HT-29 cell	In-vivo virus concentration1.0E+8 pfu	In-vivo toxicityNA	In-vivo resultCompelte reduction of tumor after 28 days	Mode of deliveryintraperitonial	Pathway inducedNA	Immunogenic effectIncrease production of IFN-gamma	Clinical trialNA	PMID12595888
IDOV_916	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo result30% reduction in tumor volume	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_917	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo result50% reduction in tumor volume	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_918	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice orthotopic xenograft for prostate cancer cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo result60% reduction in tumor volume	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_919	Virus nameHerpes simplex virus	Virus strainBaco-1	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationNon- fusogenic ligated with EGFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultLung metastasis were not detected after 40 days when stained with bouins fixative	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_920	Virus nameHerpes simplex virus	Virus strainSynco-2	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationFusogenic membrane ligated with GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultLung metastasis were not detected after 40 days when stained with bouins fixative	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_921	Virus nameHerpes simplex virus	Virus strainSynco-2D	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDouble fusogenic expressing EGFP and GALV.fus protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/cByJIcrSmnHsd-scid mice metastatic lung metastatic model	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultLung metastasis were not detected after 40 days when stained with bouins fixative	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15129429
IDOV_922	Virus nameAdenovirus	Virus strainCNHK-300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of 3 hTERT promoter in E boxes of genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSynthesized	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to 600 mm3 after 20 days as compared to control	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15243805
IDOV_923	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineOnyx pharmaceutical	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to 200 mm3 after 20 days as compared to control	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15243805
IDOV_924	Virus nameAdenovirus	Virus strainCNHK-300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of 3 hTERT promoter in E boxes of genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSynthesized	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to 200 mm3 after 20 days as compared to control	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15243805
IDOV_925	Virus nameAdenovirus	Virus strainCNHK-300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of 3 hTERT promoter in E boxes of genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSynthesized	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to 500 mm3 after 20 days as compared to control	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15243805
IDOV_926	Virus nameAdenovirus	Virus strainCNHK-300	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of 3 hTERT promoter in E boxes of genome	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineSynthesized	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreases to 400 mm3 after 20 days as compared to control	Mode of deliveryTail vein injection of virus	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID15243805
IDOV_1103	Virus nameAdenovirus	Virus strainZD55-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing ZD55 gene and IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nude mice xenograft for SW620 cell line	In-vivo virus concentration5.0E+8 cells per well	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 800mm³ as compared to control	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1104	Virus nameAdenovirus	Virus strainAd-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAdenovirus expressing IL-24 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeExpressing IL-24 gene	Source of cell lineShanghai cell collection	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nude mice xenograft for SW620 cell line	In-vivo virus concentration5.0E+8 cells per well	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume below 600mm³ as compared to control	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1105	Virus nameAdenovirus	Virus strainONYX-015	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismAthymic BALB/c nude mice xenograft for SW620 cell line	In-vivo virus concentration5.0E+8 cells per well	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction and cspase 3 activation	Immunogenic effectNA	Clinical trialNA	PMID15661558
IDOV_1136	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for HeLaS3 cell line	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 30 days	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trial	PMID15958641
IDOV_1137	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for C33A cell line	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volume after 30 days	Mode of deliveryIntratumoral injection	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trial	PMID15958641
IDOV_1138	Virus nameSindbis virus	Virus strainAR339	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for C33A cell line	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultRediction in tumor volume to 200mm after 50 days	Mode of deliveryIntravenous injection	Pathway inducedApoptosis induction in cancer cell lines	Immunogenic effectNA	Clinical trial	PMID15958641
IDOV_1146	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for Human prostatic cancer HONDA	In-vivo virus concentration2.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTotal reduction in tumor volume in 2 mice after 3 days	Mode of deliveryIntraneoplastically	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1148	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with flutamide	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for Human prostatic cancer HONDA	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume as compared to flutamide alone	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1314	Virus nameAdenovirus	Virus strainOBP-301	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for Human prostate cancer cell line LNCaP	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor size after day 20, 3 times administration	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18274558
IDOV_1351	Virus nameAdenovirus	Virus strainAdCN101	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24bp deletion between E1Ap and E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice, xenograft for BEL7404	In-vivo virus concentration2.0E+8 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 7 weeks and increase in survival	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1352	Virus nameAdenovirus	Virus strainAdCN102	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of hTERT promoter ahead of E1A	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice, xenograft for BEL7404	In-vivo virus concentration2.0E+8 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 7 weeks and increase in survival	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1353	Virus nameAdenovirus	Virus strainAdCN103	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modification24 bp deletion in hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice, xenograft for BEL7404	In-vivo virus concentration2.0E+8 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume after 7 weeks and increase in survival	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID18281783
IDOV_1384	Virus nameAdenovirus	Virus strainZD55-Ki67	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationExpressing Ki67 ShRNA	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for Human prostate cancer cell line LNCaP	In-vivo virus concentration7.0E+8 cells per well	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor size after 9 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID18690204
IDOV_1442	Virus nameAdenovirus	Virus strainZD-55-IL-18	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-18 gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice xenograft for A375	In-vivo virus concentration7.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume after 7 weeks	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis, activation of caspase 3	Immunogenic effectNA	Clinical trialNA	PMID19498459
IDOV_1727	Virus nameMeasles virus	Virus strainMV-Edm strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationMV-NPL virus , addition of P, N and L gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A-498 cells	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultSurvival rate increased in 55% of animals	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cells	Immunogenic effectInduce expression of IFN-gamma, an antiviral protein	Clinical trialNA	PMID20051938
IDOV_1728	Virus nameMeasles virus	Virus strainMV-Edm strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationMV-P virus , addition of P gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A-498 cells	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultSurvival rate increased in 11% of animals	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cells	Immunogenic effectInduce expression of IFN-gamma, an antiviral protein	Clinical trialNA	PMID20051938
IDOV_1729	Virus nameMeasles virus	Virus strainMV-Edm strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationMV-Etag virus	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A-498 cells	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultNo effect on increase in survival time	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cells	Immunogenic effectInduce expression of IFN-gamma, an antiviral protein	Clinical trialNA	PMID20051938
IDOV_2093	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of shMPP1 expressing cassette	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for SW620 cell line (5.0E+6 cells)	In-vivo virus concentration2.0E+9 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 100 mm after 9 weeks	Mode of deliveryNA	Pathway inducedInduction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID21794078
IDOV_2138	Virus nameAdenovirus	Virus strainMutant	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1BK55KD gene and addition of TRAIL gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing TRAIL gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHuh-7	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c mice xenograft for Huh7 cell line (5.0E+6 × 10⁶ pfu)	In-vivo virus concentration2.0E+9 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume below 100mm and increase in median survival time after 57 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis in cancer as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID21979578
IDOV_2209	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineCNE-2	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for CNE-2 cell line (1.0E+6 × 10⁶ cells)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultVirus treated mice shows complete regression in tumor and exhibit longer survival time	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2210	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineHongkong university	Origin of cell lineHuman nasopharyngeal carcinoma cell line	Cell lineSUNE-1	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SUNE-1 cell line (5.0E+5 × 10⁵ cells)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultVirus treated mice shows complete regression in tumor and exhibit longer survival time	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID22059912
IDOV_2211	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin	Immune gene insertion in viral genomeNo	Source of cell lineChinese academy of sciece	Origin of cell lineHuman small cell lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreased to 500mm after 57 days	Mode of deliveryIntratumoral	Pathway inducedInduction of caspase and apoptotic pathway as detected by Hoechst staining and TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22095029
IDOV_2252	Virus nameHerpes simplex virus	Virus strainHSV-1-G47-delta	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for Gamma34.5, ICP6 and alpha47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineState key laboratory of oncology China	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-435	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MDA-MB-435(1.0E+6 × 10⁶)	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume decreased by 9 fold after 56 days	Mode of deliveryIntratumoral	Pathway inducedCaspase activation	Immunogenic effectNA	Clinical trialNA	PMID22108767
IDOV_2553	Virus nameAdenovirus	Virus strainAD55-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of Apoptin gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHuh-7	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for Huh7 cell line (1.0E+7)	In-vivo virus concentration3.0E+8 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume below 425mm after 16 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apotosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID22321574
IDOV_2578	Virus nameAdenovirus	Virus strainSG600-IL-24+IFN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1B gene and insertion of IL-24 gene and addition of IN	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene and IFN gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHCCLM3	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for HCCLM3 cell line	In-vivo virus concentration2.0E+8 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume from the onset of tretament and till the end of 42 days and increase in median survival time	Mode of deliveryIntratumoral	Pathway inducedCombined therapy increases STAT1, SOCS1 and apoptosis	Immunogenic effectCombined therapy decreases expression of MMP-2, XIAP,OPN and VEGF	Clinical trialNA	PMID22569271
IDOV_2605	Virus nameAdenovirus	Virus strainAd.enAFP-E1A-delta-E1B-IL-24	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of E1A, E1B and addition of AFP and IL-24	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman liver cancer cell line	Cell lineHuh-7	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for Huh7 cell line (5.0E+6 cells)	In-vivo virus concentration4.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor after 28 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectUpregulation of GADD34	Clinical trialNA	PMID22790965
IDOV_2630	Virus nameAdenovirus	Virus strainAd-hTERT-E1a-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1a and apoptin before hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of chines academy, shanghai	Origin of cell lineHuman gastric cancer cell line	Cell lineSGC-7901	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for SGC7901 (1.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor after 9 weeks and increase in median survival time upto 55 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22842823
IDOV_2631	Virus nameAdenovirus	Virus strainAd-hTERT-E1a-Apoptin	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of E1a and apoptin before hTERT promoter	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineType culture collection of chines academy, shanghai	Origin of cell lineHuman gastric cancer cell line	Cell lineSGC-7901	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for SGC7901 (1.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume and increase in median survival time ipto 345 days	Mode of deliveryIntravenous	Pathway inducedInduction of apoptosis in cancer	Immunogenic effectNA	Clinical trialNA	PMID22842823
IDOV_2664	Virus nameAdenovirus	Virus strainSG500-dNK	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of deoxyribonucleoside kinase	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with drug dFdC (1 micromolar)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-231	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MDA-MB-231(5.0E+6 cells)	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultIncrease in median survival time to more than 100 days compared to control and reduction in tumor volume 663.85 +/- 379.39mm compared to control 1336.46 +/- 614.81	Mode of deliveryNA	Pathway inducedCombination of drug and virus increase the apoptosis process	Immunogenic effectNA	Clinical trialNA	PMID23000515
IDOV_2755	Virus nameAdenovirus	Virus strainAdCN205	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with miR-34-a	Immune gene insertion in viral genomeVirus expressing IL-24 gene	Source of cell lineATCC	Origin of cell lineHuman hepatocellular carcinoma cell line	Cell lineHuh-7	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for Huh cell (2.0E+6 cell)	In-vivo virus concentration7.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 49 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis, G1 arrest and sensescence	Immunogenic effectInhibition of oncogene and antiapototic gene	Clinical trialNA	PMID23292172
IDOV_2805	Virus nameAdenovirus	Virus strainAd.sp-E1A-TSLC1	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationDeletion of 24bp with in E1A gene and insertion of TSLC1 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549	In-vivo virus concentration5.0E+8 pfu	In-vivo toxicityNA	In-vivo resultSignificant reduction in tumor volume and increased in survival rate fro 15% to 87% at day 60	Mode of deliveryIntratumoral	Pathway inducedInduction of apotosis by virus in cancer cell line as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID23503473
IDOV_2812	Virus nameAdenovirus	Virus strainG47-delta	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with palcitaxel (16 nm)	Immune gene insertion in viral genomeNo	Source of cell lineSun-sen university cancer centre, china	Origin of cell lineHuman breast cancer cell line	Cell lineMDA-MB-468	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for MDA-MB-468 (5.0E+6 cells)	In-vivo virus concentration2.0E+5 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume after 35 days	Mode of deliveryIntratumoral	Pathway inducedMitotic arrest and induction of apoptosis	Immunogenic effectNA	Clinical trialNA	PMID23525624
IDOV_2866	Virus nameAdenovirus	Virus strainSG7605-11R-p53	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationAddition of p53 gene and 11R CPP	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineEastern hepatobility hospital	Origin of cell lineGallbladder cancer cell line	Cell lineEH-GB2	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for EH-GB2	In-vivo virus concentration1.0E+9 pfu	In-vivo toxicityNA	In-vivo resultSignficant reduction in tumor volume after day 30 and increase in median survival time	Mode of deliveryIntratumoral	Pathway inducedIncrease in apoptosis rate to 67% in cancer cell compared to normal	Immunogenic effectNA	Clinical trialNA	PMID23727990
IDOV_2931	Virus nameMeasles virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineLeukemia cell line	Cell lineU937	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for U937	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to below 12.5 mm after 14 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus alone and in combination	Immunogenic effectNA	Clinical trialNA	PMID25193462
IDOV_2932	Virus nameMumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineLeukemia cell line	Cell lineU937	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for U937	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to below 5 mm after 14 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus alone and in combination	Immunogenic effectNA	Clinical trialNA	PMID25193462
IDOV_2933	Virus nameMeasles and mumps virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationMeasles in combination with mumps	Immune gene insertion in viral genomeNo	Source of cell lineLaboratory grown own culture	Origin of cell lineLeukemia cell line	Cell lineU937	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for U937	In-vivo virus concentration1.0E+5 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed near to 2.5 mm after 14 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus alone and in combination	Immunogenic effectNA	Clinical trialNA	PMID25193462
IDOV_2934	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 274 +/- 114.20 compared to control 271.78 +/- 110.79 after day 1	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_2935	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 444.18 +/- 111.22 compared to control 591.45 +/- 244.50 after day 7	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_2936	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 657.56 +/- 176.74 compared to control 1483.21 +/- 446.75 after 14 day	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_2937	Virus nameNewcastle disease virus	Virus strainwild type	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationExpressing rl gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell linePeking university china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for A549 cell line (6.3E+8)	In-vivo virus concentration6.3E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 804.96 +/- 176.74 compared to control 1127.88 +/- 274.09 after 21 days	Mode of deliveryIntratumoral	Pathway inducedInduction of apoptosis by virus	Immunogenic effectNA	Clinical trialNA	PMID25364430
IDOV_3137	Virus nameSendai virus	Virus strainuPA2	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationDeletion of M, F gen at cytoplasmic location	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineJapan collection of research bioresources cell bank	Origin of cell lineHuman anaplastic thyroid carcinoma cell line	Cell lineKHM-5M	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBALB/c nude mice xenograft for KHM-5M cell line (2.5E+5)	In-vivo virus concentration1.0E+6 CIU per dose	In-vivo toxicityNA	In-vivo resultReduction in tumor weight and increase in survival time 41.6 +/- 15 days	Mode of deliveryIntratumoral	Pathway inducedCaspase dependent induction of apoptosis in vivo and in vitro	Immunogenic effectNA	Clinical trialNA	PMID30969451
IDOV_3175	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCAnM.Cg-Foxn1nu/Crl Balb/c nude mice subcutaneous xenograft for LNCaP (5.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 20 days	Mode of deliveryIntraperitoneal	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3176	Virus nameSemliki forest virus	Virus strainSFV-VA7	Virus genome typeRNA	Virus familyTogaviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineLNCaP	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismCAnM.Cg-Foxn1nu/Crl Balb/c nude mice subcutaneous xenograft for LNCaP (5.0E+6)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 20 days	Mode of deliveryIntraperitoneal	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28557974
IDOV_3297	Virus nameMaraba virus	Virus strainMG1	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineMurine sarcoma cell line	Cell lineS180	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice isograft for S180 mouse tumor cell line (1.0E+6)	In-vivo virus concentration1.0E+8 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor volume after 97 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectGenration of memory immune response by incresing production of cytokines	Clinical trialNA	PMID28568891
IDOV_3298	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 81.1% as compared to control 100% after day 3	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3299	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 89.7% as compared to control 100% after day 5	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3300	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 80.7% as compared to control 100% after day 8	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3301	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 71.9% as compared to control 100% after day 10	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3302	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 68.1% as compared to control 100% after day 12	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3303	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 58.4% as compared to control 100% after day 15	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3304	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 57.1% as compared to control 100% after day 17	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3305	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 58.3% as compared to control 100% after day 19	Mode of deliveryIntratumoral	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3306	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 67.8% as compared to control 100% after day 3	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3307	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 60.8% as compared to control 100% after day 5	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3308	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 62.4% as compared to control 100% after day 8	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3309	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 64.7% as compared to control 100% after day 10	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3310	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 64.4% as compared to control 100% after day 12	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3311	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 61.5% as compared to control 100% after day 15	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3312	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 59.7% as compared to control 100% after day 17	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3313	Virus nameNewcastle disease virus	Virus strainR2B mukteshwar strain	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineHuman colon cancer cell line	Cell lineSW620	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultTumor volume become 59.9% as compared to control 100% after day 19	Mode of deliveryIntravenous	Pathway inducedInduction of necrosis and apoptosis in animal model cancer cell line	Immunogenic effectNA	Clinical trialNA	PMID28578522
IDOV_3498	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 700mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3499	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 100mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3500	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549-DDPR cisplatin resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 800mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3501	Virus nameAdenovirus	Virus strainAdenovirus CRAds	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationNone	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with cisplatin	Immune gene insertion in viral genomeNo	Source of cell lineCell collection centre china	Origin of cell lineHuman lung cancer cell line	Cell lineA549-DDPR cisplatin resistant	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for SW-620 cell line (1.0E+6)	In-vivo virus concentration8.0E+6 pfu	In-vivo toxicityNA	In-vivo resultTumor size regressed to 300mm compared to control 900mm after 65 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID28638457
IDOV_3520	Virus nameAdenovirus	Virus strainAdenovirus ZD55-shMYCN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing MYCN gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineLab own synthesized	Origin of cell lineHuman neuroblastoma cell line	Cell lineLA1-55n/Dox-R	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for LA1-55n/Dox-R cell line (2.0E+6)	In-vivo virus concentration7.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 800mm after four week compared to normal 1400 mm.	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28711493
IDOV_3521	Virus nameAdenovirus	Virus strainAdenovirus ZD55-shMYCN	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressing MYCN gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Doxorubicin	Immune gene insertion in viral genomeNo	Source of cell lineLab own synthesized	Origin of cell lineHuman neuroblastoma cell line	Cell lineLA1-55n/Dox-R	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for LA1-55n/Dox-R cell line (2.0E+6)	In-vivo virus concentration7.0E+8 pfu	In-vivo toxicityNA	In-vivo resultTumor volume regressed to 300mm after four week compared to normal 1400 mm.	Mode of deliveryNA	Pathway inducedInduction of apoptosis as measured by TUNEL assay	Immunogenic effectNA	Clinical trialNA	PMID28711493
IDOV_3618	Virus nameAdenovirus	Virus strainAdenovirus CD55-TRAIL	Virus genome typeDNA	Virus familyAdenoviridae	Virus genome modificationVirus expressingTRAIL gene	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with luteolin (50mg/kg)	Immune gene insertion in viral genomeNo	Source of cell lineShanghai cell collection	Origin of cell lineHuman colorectal cancer cell line	Cell lineHT-29	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c nude mice xenograft for HT29 cell line (8.0E+6)	In-vivo virus concentration2.0E+9 pfu	In-vivo toxicityNA	In-vivo resultDecrease in tumor volume to below 2000mm after 30 days comapred to control 4000mm	Mode of deliveryIntratumoral	Pathway inducedVirus in combination with induce apiptosis in cancer cell	Immunogenic effectNA	Clinical trialNA	PMID29039580
IDOV_3737	Virus nameVesicular stomatitis virus	Virus strainVSV-GP	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman prostate cancer cell line	Cell lineDu145	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismBalb/c-rag and gamma negative xenograft for Du145 (2.0E+6)	In-vivo virus concentration1.0E+7 pfu	In-vivo toxicityNA	In-vivo resultComplete regression in tumor after day 80	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID29696636